Weight loss jabs like Ozempic can cut the risk of heart attacks or strokes by a fifth, a “game-changing” new study has found. The anti-obesity injections could reduce the risk in obese people ...
Find your bookmarks in your Independent Premium section, under my profile Weight loss jabs like Ozempic can cut the risk of heart attacks or strokes by a fifth, a “game-changing” new study has ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug, researchers have found.
A groundbreaking study has revealed that an anti-obesity jab containing semaglutide, a drug used to treat obesity, significantly reduces the risk of heart attacks and strokes, regardless of the ...
The drug Wegovy uses an active ingredient called Semaglutide, which is part of a growing class of GLP-1 drugs that make ...
Anti-obesity injections could lower the chances of serious heart disease in overweight individuals, regardless of their weight loss while on the medication, according to new research. A new study ...
Obesity jabs could cut the risk of heart attacks and strokes in people even if they fail to lose much weight, according to an analysis of a study funded by a drug manufacturer. Researchers looked ...
A weight loss injection could reduce the risk of heart attacks and benefit the cardiovascular health of adults, according to a study on what could be the largest medical breakthrough since statins.
Delivered via an injection into the skin, the drug makes people feel fuller and more satisfied, so they eat less Obesity jabs could cut the risk of heart attacks and strokes in people even if they ...
Semaglutide, also known as Ozempic or Wegovy, is set to transform treatments for cardiovascular disease, but a change in ...
An anti-obesity drug could have additional health benefits including reducing the risk of heart attacks and strokes a new study has revealed. A five-year study was carried out by a team led ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three years of treatment, according to an analysis of data from the five-year ...